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The purpose of this study was to compare the diagnostic interest of Hector Battifora mesothelial antigen-1 (HBME-1), thyroid
peroxidase (TPO), and dipeptidyl aminopeptidase IV (DPP4) in thyroid fine-needle aspirates obtained from 200 resected thyroid
lesions (55 colloid nodules, 54 follicular adenomas, 59 papillary cancers, and 32 follicular carcinomas). Hector Battifora mesothelial
antigen-1 or TPO expression (% positive cells) and DPP4 staining score (12-point scale) were evaluated. Receiver operating
characteristic (ROC) curves were plotted and optimal cutoff values for diagnosing malignancy were determined. The TPO ROC
curve was consistently higher than the HBME-1 ROC curve. The TPO curve was also higher than the DPP4 curve with regard to
sensitivity, but dipped below the DPP4 curve with regard to specificity. Using a cutoff value of o80% positive cells for TPO, 410%
positive cells for HBME-1, and staining score X1 for DPP4, sensitivity to specificity ratios were 98–83% for TPO, 90–60% for
HBME-1, and 88–80% for DPP4. Two particularly interesting findings of this study were the low negative likelihood ratio of TPO
(0.02) allowing highly reliable exclusion of malignancy and the 100% specificity of DPP4 staining scores¼12. Due to poor
performance on follicular lesions, HBME-1 showed no advantage over TPO or DPP4.
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Fine-needle aspiration (FNA) biopsy is the most effective method
for preoperative evaluation of thyroid nodules (Cooper et al, 2006).
This efficacy depends mainly on the fact that almost 70% of
thyroid nodules are benign macrofollicular lesions that can be
reliably identified in cytological smears, and that fewer than 5%
are malignant tumours including 70% of papillary cancers (PCs)
that can also be reliably identified on FNA. However, overlapping
cytological features can hinder diagnosis in the remaining 25%
cases. Fine-needle aspiration biopsy cannot distinguish benign
from malignant microfollicular tumours that require examination
on histological sections. It can be difficult to distinguish between
hyperplastic nodules and follicular tumours and to recognize the
follicular variant of PC (De Micco et al, 1999). Because of these
drawbacks, FNA smears presenting microfollicular or hyper-
cellular pattern are classified as follicular neoplasm, a ‘grey zone’
of thyroid FNA (Baloch et al, 2002).
Various methods have been proposed to assist thyroid cytology
on FNA. Molecular methods such as mutation detection or
expression profile analysis are promising but cannot currently be
used for routine practice (Eszlinger et al, 2006; Griffith et al, 2006;
Lubitz et al, 2006; Tetzlaff et al, 2006; Finn et al, 2007). On the
contrary, immunocytochemistry (ICC) and cytoenzymology (CE)
are widely available and can be performed on smears (De Micco
et al, 1994a), cell blocks (Sack et al, 1997), or liquid-based
preparation (Rossi et al, 2005). Out of several markers that have
been investigated, the most attractive for diagnosis on thyroid FNA
are Hector Battifora mesothelial antigen-1 (HBME-1), thyroid
peroxidase (TPO), and dipeptidyl aminopeptidase IV (DPP4)
because they can be used directly on smears.
Thyroid peroxidase is a membrane thyroid enzyme essential for
thyroid hormone synthesis. It is present in large quantity in the
cytoplasm of all benign thyrocytes. In malignant tumours, TPO
synthesis is inhibited to varying degrees and maturation is
deregulated resulting in overexpression of short splice variants
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s(De Micco et al, 2000; Di Cristofaro et al, 2006). According to gene
expression profiling analysis in thyroid cancer vs non-cancer
tissue, TPO was one of the top 12 candidate markers in terms of
diagnostic utility (Griffith et al, 2006). The TPO immunoreactivity
is reduced in malignant cells especially in response to antibodies
reacting with the native form such as the monoclonal antibody 47
(MoAb 47) (De Micco et al, 1991). Previous studies (De Micco
et al, 1994a; Faroux et al, 1997; De Micco et al, 1998; Christensen
et al, 2000) have confirmed the value of TPO ICC using MoAb 47
on smears.
Dipeptidyl aminopeptidase IV is an exopeptidase identical to
cluster antigen CD26. Encouraging results have been obtained
using DPP4 CE for diagnosis of thyroid malignancy on FNA
material (Aratake et al, 1992; Zoro et al, 1996). A high-contrast red
stain appears on the cellular membrane in malignant thyroid cells.
Detection of DPP4 activity on smears is simple, fast, and
inexpensive.
Hector Battifora mesothelial antigen-1 is a monoclonal antibody
raised against cultured mesothelial cells. It reacts with an unknown
antigen on the surface of mesothelial cells and in various
adenocarcinomas and sarcomas (Miettinen and Karkkainen,
1996). Hector Battifora mesothelial antigen-1 immunohisto-
chemistry is usually negative in benign thyroid lesions and
positive on carcinomas. Most studies using HBME-1 for diagnosis
of thyroid tumours have been performed on tissue samples (Mai
et al, 2002; Ito et al, 2005; Papotti et al, 2005; Prasad et al, 2005). A
few studies using FNA products have been carried out on cell
blocks or thin layers (Sack et al, 1997; van Hoeven et al, 1998;
Rossi et al, 2005; Saggiorato et al, 2005). We have developed an
HBME-1 staining technique for air-dried thyroid FNA smears. The
purpose of this report is to compare the utility of HBME-1, TPO,
and DPP4 for diagnosing thyroid malignancy on FNA smears.
MATERIALS AND METHODS
FNA smears
Smears were made using FNA samples obtained from 200 thyroid
lesions investigated and removed in the Department of Endocrine
Surgery from 1993 to 2006 (Timone University Hospital,
Marseilles, France). There were 55 benign colloid nodules (CNs),
54 follicular adenomas (FAs) including seven cases with limited
nuclear features of papillary thyroid cancers (LNFPTCs) and six
with Hu ¨rthle cells, 59 PCs including 19 follicular variants (PCFVs),
and 32 follicular carcinomas (FCs) including 9 Hu ¨rthle cell
carcinomas. None of these tumours were hyperfunctioning.
Consecutive cases were selected from hospital files according to
the WHO’s classification-based registered histological diagnosis
and to the availability of FNA material.
Pre-operative work-up included FNA in all patients. Thyroid
peroxidase and DPP4 analysis were routinely performed on three
slides (two TPO and one DPP4) as previously described (De Micco
et al,1994a; Zoro et al, 1996). The material was spread on super-
frost slides (CML, Nemours, France), air dried, and either stored at
þ41C to be stained within 72h (100 cases) or frozen at  201C for
future staining (100 cases).
Hector Battifora mesothelial antigen-1 analysis and controls
were performed on smears made from additional FNA obtained
from the resected nodule in the surgery room, air dried, and
immediately frozen and stored at  201C.
This study protocol was approved by the clinical research
committee of Marseille Public Hospital System.
TPO and HBME-1 immunocytochemistry
After neutralisation of endogenous peroxidase in a phosphate-
buffered saline (PBS) solution containing 0.1% hydrogen peroxide
(H2O2) for 5min, slides were incubated overnight at þ41C with
anti-TPO monoclonal antibody (MoAb 47 clone; Dako, Glostrup,
Denmark) diluted to 1:100 (2mgml
 1). Revelation was performed
using a streptavidin–biotin–peroxidase kit with 3,30-diamino-
benzidine (LSAB; DAKO, Glostrup, Denmark). The percentage of
positive cells was evaluated. Cells exhibiting an abnormal staining
pattern, that is, low intensity with coarse granules at the periphery
of the cytoplasm with no perinuclear ring, were not considered as
positive. Positive controls were performed on smears from
operated benign nodules. Negative controls were performed by
omitting the primary antibody.
Primary anti-HBME antibody was used at a dilution of 1:100
(1mgml
 1) and the reaction was performed using an automated
immunoperoxidase procedure in the Ventana Benchmark device
(Ventana kit; Ventana, Tucson, AZ, USA). Results were evaluated
without knowledge of the final histological diagnosis and that of
the results of TPO and DPP4 reactions. Two independent observers
(CDM and VK) evaluated the percentage of positive cells, and the
final results corresponded to the mean of the assessments. Smears
using the same techniques on PCs were performed as positive
controls.
DPP4 cytoenzymology
Detection of DPP4 activity was performed as follows:
  fixation for 1min in a mixture of formalin, cold acetone, and
PBS (0.15moll
 1, pH 7.4) at a ratio of 1:40:10 respectively;
  rinsing with water;
  immersion for 30min at room temperature in a solution
containing 3mg glycyl proline 4-b naphthylamide, 0.25ml N,N-
dimethylformamide, and 5mg fast blue B salt in 4.6ml sodium
phosphate buffer (0.1moll
 1, pH 7.2);
  rinsing with water;
  counterstaining with haematoxylin for 10s and mounting with
water.
Positive reactions are characterized by contrasted red staining of
the cytoplasm and plasma membrane. Staining was scored using a
discontinuous 0–12-point scale as described previously (Aratake
et al, 1992). Positive controls were performed on smears from
operated malignant nodules.
Statistical analysis
SPSS software (version 13.0, 2004 SPSS Inc., Chicago, IL, USA) was
used for statistical analysis. A Po0.05 was considered statistically
significant. Receiver operating characteristic (ROC) curves were
constructed to compare the diagnostic performance of the three
markers and the area under the ROC curve (AUC) was computed
(Hanley and McNeil, 1982). Cutoff values resulting in optimal
sensitivity (Se) to specificity (Sp) ratios were determined based on
the ROC curves. In addition to Se and Sp, positive and negative
likelihood ratios (LRþ and LR ) were calculated.
RESULTS
Thyroid peroxidase ICC and DPP4 staining performed on control
smears obtained from nodules after surgical resection showed no
significant differences as compared with pre-surgically obtained
FNA samples. Indeed, the higher proportion of epithelial to red
blood cells observed in post-surgical FNAs did not modify the
pattern of staining of the markers or the ratio of positive to
negative epithelial cells. Reactions for TPO, DPP4, and HBME1
performed on control slides stored at þ41C or frozen at  201C for
up to 10 years were also undistinguishable.
Results obtained with TPO, HBME-1, and DPP4, based on
definitive histological diagnosis, are shown in Tables 1 and 2.
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sOverall, clearly positive or negative reactions were obtained in
146–163 of the cases depending on the marker used. However,
intermediate reactions with overlapping of benign and malignant
tumours were observed in other cases.
Immunostaining of TPO was highly positive (X80% positive
cells) in 90 (51 CNs and 39 FAs) out of the 109 benign nodules. The
reaction was characterised by dark-brown granular staining of the
cytoplasm with halo around nuclei (Figure 1A). Two nodules (one
CN and one FA) were negative and 17 (three CNs and 14 FAs)
exhibited varying percentages of positive cells. Three positive FAs
contained LNFPTCs and four contained Hu ¨rthle cells. The TPO
reaction was negative or low grade (p10%) in 52 out of the 91
carcinomas (41 PCs and 11 FCs) and positive (100%) in two PCs.
Both positive PCs were PCFVs and one presented as a benign CN
including foci of microcarcinoma. Intermediate TPO immuno-
staining (20–70%) was observed in the remaining 37 carcinomas,
that is, 16 PCs and 21 FCs. Tall-cell tumours and tumours with
Hu ¨rthle cell features exhibited an abnormal reaction pattern
characterized by pale granular staining beneath the cellular
membrane with absence of the nuclear halo.
Immunostaining of HBME-1 was negative or low grade (p10%
positive cells) in 65 out of the 109 benign nodules (37 CNs and 28
FAs), and high grade (X80%) in 14 including five CNs and nine
FAs. Intermediate staining (20–70%) was observed in the
remaining 30 cases. Nine of the positive benign nodules exhibited
LNFPTCs and six were made of Hu ¨rthle cells. Strong membrane
staining sometimes associated with a diffuse cytoplasmic reaction
involving more than 70% of cells was observed in 71 out of the 91
carcinomas (Figure 1B). Weaker intermediate staining (20–70%
positive cells) was observed in 10 PCs and four FCs. Five PCs
and four FCs showed low-grade staining (p10%). Four out of
these five PCs were PCFVs and one contained multiple foci of
microcarcinomas within a CN. Out of the four negative FCs, one
was made of Hu ¨rthle cells, two were minimally invasive, and one
was highly invasive and poorly differentiated.
Staining scores of DPP4 were negative or light (p1) in 87 out of
the 109 benign nodules, including 45 CNs and 42 FAs, and clearly
positive (44) in seven FAs. Intermediate scores were obtained in
the remaining 15 cases. Three positive benign nodules contained
LNFPTCs and three were made of Hu ¨rthle cells. In the 91
carcinomas, scores X6 were obtained in 62 cases (Figure 1C).
However, 11 carcinomas (four PCs and seven FCs) had scores p1.
Three PCs were PCFVs, three FCs contained Hu ¨rthle cells, three
were minimally invasive, and one was a poorly differentiated
insular tumour.
To determine the best cutoff values for diagnosis of malignancy,
ROC curves were constructed and analysed (Figure 2). The AUC
was 0.95 (IC 95%: 0.92–0.98) for TPO, 0.90 (IC 95%: 0.86–0.95) for
DPP4, and 0.86 (IC 95%: 0.81–0.92) for HBME. These differences
were not significant. However, the TPO ROC curve was always
entirely above the HBME-1 ROC curve and above the DPP4 ROC
curve in the segment corresponding to high sensitivity. It crossed
the DPP4 ROC curve to get under it in the segment corresponding
to high specificity. Optimal Se to Sp ratios were observed using the
following cutoff values for malignancy: X1 for DPP4 staining
score, 410% positive cells for HBME-1, and o80% positive cells
for TPO. With these cutoffs, Se was 0.89 (IC 95%: 0.79–0.95) for
DPP4, 0.90 (IC 95%: 0.82–0.95) for HBME-1, and 0.98 (IC 95%:
0.92–1) for TPO; Sp was 0.60 (IC 95%: 0.50–0.69) for HBME-1,
0.80 (IC 95%: 0.71–0.86) for DPP4, and 0.83 (IC 95%: 0.74–0.89)
for TPO.
Calculation of LRþ and LR  yielded values of 2.5 and 0.17,
respectively, for HBME-1; 5.8 and 0.02, respectively, for TPO; and
4.4 and 0.15, respectively, for DPP4. One nodule, that is, a
multifocal micropapillary carcinoma within an adenoma, was false
negative with all three markers. Three other nodules, that is, one
PCFV and two minimally invasive FCs, were false negatives with
HBME-1 and DPP4. Maximum Sp values were 0.97 (IC 95%: 0.92–
0.99) with HBME-1, 0.98 (IC 95%: 0.93–1) with TPO, and 1 with
DPP4, using cutoff values of X90% positive cells for HBME,
p10% positive cells for TPO, and a score of 12 for DPP4. The Se
with these cutoffs was 0.46 (IC 95%: 0.36–0.37) for DPP4, 0.55 (IC
95%: 0.44–0.65) for HBME-1, and 0.57 (IC 95%: 0.46–0.67) for
TPO. One CN and five FAs were false positive with HBME-1 and
TPO.
DISCUSSION
Thyroid peroxidase ICC using MoAb 47 and DPP4-activation
detection were the first malignancy markers reported to have a
diagnostic significance on thyroid FNA smears (Aratake et al,
1992; De Micco et al, 1994a). In large series, TPO has been shown
to have Se of 98% and Sp of 80% (Faroux et al, 1997; De Micco
et al, 1998; Christensen et al, 2000). Dipeptidyl aminopeptidase IV
Table 1 Thyroid peroxidase and HBME immunocytochemistry on FNA smears from 200 thyroid tumorss
% of positive cells
Histology Ab 0 10 20 30 40 50 60 70 80 90 100
CN (n¼55) TPO 1 0 1 0 0 2 0 0 5 3 43
HBME 32 5 8 0 3 1 1 0 4 0 1
FA (n¼54) TPO 1 0 0 1 3 4 5 1 13 3 23
HBME 19 9 5 0 4 4 2 2 4 1 4
PC (n¼59) TPO 28 13 4 0 2 6 2 2 0 0 2
H B M E32 212122 1 3 22 9
FC (n¼32) TPO 4 7 7 4 4 2 4 0 0 0 0
H B M E40 001111 5 11 8
CN¼colloid nodule, FA¼follicular adenoma, FC¼follicular carcinoma, FNA¼fine-needle aspiration, HBME¼Hector Battifora mesothelial antigen, PC¼papillary carcinoma.
The table presents the number of cases.
Table 2 Scores of DPP4 activity according to histological diagnoses
Staining scores
Histology 0 1 2 3 4 6 9 12
CN (n¼55) 43 2 8 2 0 0 0 0
FA (n¼54) 41 1 2 1 2 6 1 0
PC (n¼5 9 ) 40121773 7
FC (n¼3 2 ) 6163533 5
CN¼colloid nodule, DPP4¼dipeptidyl aminopeptidase IV, FA¼follicular adenoma,
FC¼follicular carcinoma, PC¼papillary cancer. The table presents the number of
cases.
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staining method is simple to perform on air-dried smears and is
inexpensive, we routinely carry out DPP4 analysis in conjunction
with TPO ICC at our institution to assist thyroid FNA.
A number of other molecules have been described later on as
malignancy markers for thyroid carcinoma. Three of them, that is,
HBME-1, galectine-3 (GAL3), and cytokeratine-19 (CK19), have
been tried on cytological material and are considered useful
(van Hoeven et al, 1998; Saggiorato et al, 2005; Rossi et al, 2006).
However, almost all these studies were performed on cell blocks or
thin-prep samples because of poor results on conventional smears.
At our institution, unsuitability for use on FNA smears has been a
major drawback for the routine use of HBME-1, GAL3, and CK19
when compared with TPO and DPP4. Indeed, the need to perform
cell blocks or thin-prep preparations in addition to smears
introduced an excessive increase in both procedure cost and time,
when two methods efficient on smears were already available.
Recently, we successfully developed an HBME-1 staining technique
on FNA smears using an automated immunoperoxidase procedure
in the Ventana Benchmark device. Then, comparison with other
markers performed on FNA smears became possible.
In the present series, we compared the performance of TPO,
DPP4, and HBME-1 on FNA smears obtained from 200 thyroid
nodules before or after surgical resection. We performed ROC
analysis to compare the results and determine optimal cutoff
values for diagnosis of malignancy (Hanley and McNeil, 1982).
Positive and negative LR were calculated for a better estimation of
the diagnostic value independent of the proportion of histological
types of tumours in the series (Jaeschke et al, 1994).
Fine-needle aspiration biopsy performed on resected thyroid
nodules represents a useful tool for the analysis of molecular
markers. Except for varying amount of blood, the properties of
smears taken before and after surgical resection are basically
identical. In our experience, thyroid FNA stored at  201C for more
than 10 years retained their morphology and immunostaining
properties for all the investigated antigens (thyroglobulin,
thyrocalcitonin, thyroid transcription factor 1, TPO, and HBME-1),
provided that they were performed and frozen immediately after
resection. As our results of HBME ICC on FNAC obtained on
resected nodule are very similar to those previously reported on
FNAC obtained percutaneously (Sack et al, 1997; Rossi et al, 2005),
it is reasonable to assume that these differences in FNA sampling
methods had no significant influence on ICC.
Results with TPO were similar to those in previous studies (De
Micco et al, 1994a,b, 1999; Faroux et al, 1997; Christensen et al,
2000). Optimal performances for diagnosing malignancy, with Se
A
B C
Figure 1 Pattern of positive staining of TPO, HBME, and DPP4. (A) Staining of TPO in benign follicular adenoma: brown granular deposit all over the
cytoplasm and around the nuclei. (B) Staining of HBME in papillary cancer: brown reaction predominant on cellular membranes. (C) Staining of DPP4 in
papillary cancer: contrasted red reaction within cytoplasm and along membranes.
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Figure 2 Receiver operating characteristic curves obtained with thresh-
old values from 0 to 100% for TPO, 100 to 0% for HBME, and 12 to 0 for
DPP4. *Threshold values resulting in the best sensitivity for each marker.
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sof 98% and Sp of 83%, were obtained using a cutoff value of o80%
positive cells. All FCs and 72% of FAs were correctly diagnosed.
Almost half of the false-positive results concerned follicular tumours
with either LNFPTC or Hu ¨rthle features. This finding corroborates
molecular studies showing that these borderline tumours may
represent an intermediate form between benign and malignant
tumours (Vasko et al, 2004). Two false negatives were heterogeneous
FVPTCs occurring in benign CNs. The errors were probably due to
inadequate sampling, resulting in discrepancies from slide to slide.
As previously reported (Zoro et al, 1996), DPP4 was reliable
for diagnosis of classical PCs, but the cutoff for diagnosing
malignancy (X1) was lower. The high proportion of malignant
tumours in this series may account for this difference. Sensitivity
of DPP4 for malignant follicular tumours including the FVPTC
was low with a misdiagnosis rate of 20–30%, especially with
tumours presenting Hu ¨rthle or tall-cell features. This high
false-negative rate reduces the utility of DPP4 for diagnosis of
follicular tumours. Despite this limitation, we still consider DPP4
useful because positive results are highly specific.
To our knowledge, all but two previous studies of HBME on
thyroid FNA (Sack et al, 1997; Rossi et al, 2005) were carried
out on cell blocks (van Hoeven et al, 1998; Saggiorato et al, 2005).
However, overall results obtained on fresh tissue, including our
study, and cell blocks are rather concordant. The sensitivity of
HBME-1 staining was excellent (490%) for classical PC (van
Hoeven et al, 1998; Ito et al, 2005; Rossi et al, 2005), disappointing
for PCFV, and poor (o65%) for follicular and undifferentiated
cancers (Cheung et al, 2001; Mai et al, 2002; Ito et al, 2005; Prasad
et al, 2005; Saggiorato et al, 2005). The reported specificity of
HBME-1 staining ranged from 70% to more than 90% (Cheung
et al, 2001; Prasad et al, 2005; Saggiorato et al, 2005). Thyrotoxic
hyperplasia was consistently negative (Rossi et al, 2006) whereas
nodular goitres were positive in up to 17% of cases (Ito et al, 2005).
Significant reactions were also reported in 25% of thyroiditis
(Prasad et al, 2005), 5–10% of benign follicular tumours devoid of
atypical features, and up to 65% with LNFPTC or Hu ¨rthle cell
features (Mai et al, 2002; Papotti et al, 2005; Prasad et al, 2005;
Scognamiglio et al, 2006). The fact that specificity in our study was
in the lower range may be due to a high proportion of atypical or
Hu ¨rthle cell tumours and absence of hyper-functional nodules.
Receiver operating characteristic analysis showed that all
three markers improved the performance of thyroid FNA,
with AUCs above 0.8 in comparison with values between 0.58
and 0.74 obtained in a recent analysis in which performance
of 11 cytologists was measured using AUC (Raab et al, 2006).
Comparison of the three ROC curves indicated that the
sensitivity of TPO was superior to that of HBME-1 and DPP4
and its specificity was also superior to that of HBME-1.
This difference was mainly due to the greater ability of TPO to
differentiate benign from malignant follicular proliferations,
including PCFV and Hu ¨rthle cell tumours. As a result, LR 
was significantly lower for TPO ICC (0.02) than either DPP4 (0.12)
or HBME-1 (0.17). According to Jaeschke et al (1994),
LR  values of less than 0.1 are highly significant, whereas
values of 0.1–0.2 are only moderately conclusive.
It should be noted that a previous study comparing the
diagnostic value of HBME1 and TPO on cell blocks yielded
different results, that is, lower Se (80%) and higher Sp (96 and
86%, respectively) for both markers (Saggiorato et al, 2005).
Several possible explanations can be proposed for this difference.
The cell-block methodology may not have been sensitive
enough for precise determination of the percentage of positive
cells. Evaluation of immunostaining was semiquantitative
and ROC analysis was not used to compare marker performance.
Cutoff values for the diagnosis of malignancy were determined
empirically. The cutoff value retained to separate benign
from malignant tumours based on TPO ICC in the study by
Saggiorato et al was 50% of positive cells, whereas the cutoff
value determined to provide the best results in previous
ROC analysis as in the present study was 80% of positive cells
(Faroux et al, 1997).
This study comparing malignancy marker staining on
smears from thyroid FNA confirms our previous findings
that TPO ICC is the most sensitive method for diagnosis of
malignancy and enhances the specificity of standard cytology.
Hector Battifora mesothelial antigen-1 ICC provides no advantage
over TPO and assessment of the staining pattern is more
difficult. Although its sensitivity is low, detection of DPP4 activity
presents several advantages including 100% specificity for staining
scores of 12.
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